Get the Stockscreener App
5.25
1.13%
-0.06
After Hours:
5.49
0.24
+4.57%
Candel Therapeutics Inc stock is traded at $5.25, with a volume of 820.85K.
It is down -1.13% in the last 24 hours and down -33.63% over the past month.
See More
Previous Close:
$5.31
Open:
$5
24h Volume:
820.85K
Relative Volume:
0.67
Market Cap:
$247.99M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.1065
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-24.46%
1M Performance:
-33.63%
6M Performance:
-21.76%
1Y Performance:
+212.50%
1-Day Range:
$4.9551
$5.33
1-Week Range:
$4.9551
$6.97
52-Week Range:
$2.00
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.25 | 247.99M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire
Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks
Breakthrough: New Brain Cancer Therapy Doubles Survival Time in Key Patient Group - Stock Titan
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga
Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news
Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz
Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener
Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - MarketScreener
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors UK
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - GlobeNewswire
Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada
Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa
Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada
Candel therapeutics CEO sells $229,624 in stock - Investing.com India
Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView
Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com
Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq
Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - MarketScreener
Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire
Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan
Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com India
Candel therapeutics CFO Charles Schoch sells $44,169 in stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK
Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive financial news
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board - The Manila Times
Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire
Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com India
When (CADL) Moves Investors should Listen - Stock Traders Daily
Candel Therapeutics Reports Positive Clinical Trial Results - TipRanks
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline - Proactive financial news
Candel Therapeutics, Inc. SEC 10-K Report - TradingView
Candel Therapeutics Reports Positive Data from Multiple Clinical Trials and Outlines Plans for CAN-2409 and CAN-3110 - Nasdaq
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):